<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 30, 2000
-----------------
VIRAGEN, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-10252 59-2101668
---------------------------- ------------------------ ----------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
865 S.W. 78TH AVENUE, SUITE 100, PLANTATION, FL 33324
------------------------------------------------------------- --------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (954) 233-8746
--------------
----------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
<PAGE> 2
Item 5. OTHER EVENTS
On December 6, 2000, Viragen, Inc. announced that it had entered into a
collaborative project with the Roslin Institute. The collaborative project
involves avian transgenic technology. This technology will enable biotech and
pharmaceutical companies to produce drugs inside the eggs of specially
developed chickens.
Additionally, Viragen entered into a common stock purchase agreement with
Ladenburg Thalmann & Co., Inc. on November 30, 2000. Under the terms of the
agreement, Ladenburg Thalmann will purchase an aggregate $2,500,000 of our
common stock during the pricing period December 7, 2000 through January 11,
2001 in one or more installments. The common stock will be sold at a price
based upon market price during the period. The common stock will be issued
pursuant to our shelf registration on Form S-3 (File No. 333-32306).
2
<PAGE> 3
Item 7. EXHIBITS
1. Viragen, Inc. Press Release dated December 6, 2000
2. Common Stock Purchase Agreement between Viragen, Inc.
and Ladenburg Thalmann & Co., Inc. dated November 30, 2000
3
<PAGE> 4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VIRAGEN, INC.
---------------------------------
(Registrant)
Date: December 5, 2000 /s/ Dennis W. Healey
---------------------------------
Dennis W. Healey
Executive Vice President and
Principal Financial Officer
4
